OrbiMed Raises $4.3B Across Three Private Funds

OrbiMed, one of the largest global financers of private and public biopharma companies, raised $4.3 billion across three funds to invest in healthcare and life sciences startups.

The capital was raised for OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV.

The funds allow the New York-based hedge fund with over $17 billion in assets to invest globally, from seed stage for startups incubated by OrbiMed through growth capital opportunities.

Comprised of 21 partners, OrbiMed focuses on healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and tech-enabled healthcare services, providing equity, credit and royalty-based financing.

“OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds,” said Carter Neild, a managing partner of OrbiMed. “We will endeavor to meet our partners’ high expectations in the coming years.”